Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Generic Drug Review Costs Still Largely Non-Personnel Related

Executive Summary

Despite a recent hiring binge, FDA's ANDA evaluation expenses continue to be driven by infrastructure and equipment.


Related Content

Biosimilars At US FDA: Personnel Spending Losing Influence Over Program
GDUFA: Review Costs Continued To Climb Once Formal Review Goals Began
Risk-Based Inspections Might Actually Be Hurting Compliant Firms
FDA Globalization Capacity, Shortage Monitoring Remain Concerns, GAO Says
FDA’s Rent Is Too Damn High: Consolidated Labs Cost More Than Off-Campus Space
FDA GMP “Surveillance” Will Link Quality, Compliance Information To Inspections





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts